Cargando…

An insight about genomic susceptibility & multiple sclerosis

Detalles Bibliográficos
Autores principales:	Verma, Rajesh, Singh, Neetu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674538/ https://www.ncbi.nlm.nih.gov/pubmed/29067970 http://dx.doi.org/10.4103/ijmr.IJMR_725_17

Ejemplares similares

Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
por: Vermersch, Patrick, et al.
Publicado: (2019)

Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology
por: Calabresi, Peter A., et al.
Publicado: (2010)

Tolerogenic vaccines for Multiple Sclerosis
por: Mannie, Mark D., et al.
Publicado: (2013)

Luteolin as a therapeutic option for multiple sclerosis
por: Theoharides, Theoharis C
Publicado: (2009)

The Extracellular Matrix and Remyelination Strategies in Multiple Sclerosis
por: You, Yuyi, et al.
Publicado: (2018)

European and American Guidelines for Multiple Sclerosis Treatment
por: Ghezzi, Angelo
Publicado: (2018)

Chewing the fat on an emerging target in multiple sclerosis
por: Lim, Chai K.
Publicado: (2021)

Seeking neuroprotection in multiple sclerosis: an ongoing challenge
por: Antel, Jack P., et al.
Publicado: (2023)

Multiple sclerosis: major histocompatibility complexity and antigen presentation
por: Ramagopalan, Sreeram V, et al.
Publicado: (2009)

Serum markers of multiple sclerosis - a new approach
por: Torkildsen, Øivind
Publicado: (2021)

B cells and multiple sclerosis spinal cord pathology
por: Schmierer, Klaus, et al.
Publicado: (2020)

Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful
por: Avolio, Carlo, et al.
Publicado: (2021)

Monkeypox in Multiple Sclerosis patients: Should we be alert?
por: Boldrini, Vinícius Oliveira, et al.
Publicado: (2022)

Open Transparent Communication about Animals in Laboratories: Dialog for Multiple Voices and Multiple Audiences
por: Carbone, Larry
Publicado: (2021)

Neural connectivity abnormalities in autism: Insights from the Tuberous Sclerosis model
por: Tye, Charlotte, et al.
Publicado: (2013)

Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier
por: Yeandle, David, et al.
Publicado: (2018)

Fungal microbiome and multiple sclerosis: The not-so-new kid on the block
por: Mangalam, Ashutosh K.
Publicado: (2021)

Similarities and differences between multiple sclerosis and type 1 diabetes
por: Pozzilli, Valeria, et al.
Publicado: (2021)

Honing in on magnetic resonance imaging predictors of multiple sclerosis pathology
por: Schmierer, Klaus
Publicado: (2023)

A multiple sclerosis patient-oriented multiomics analysis tells us where to go next: Commentary for: “Alterations of host-gut microbiome interactions in multiple sclerosis”
por: Yamamura, Takashi, et al.
Publicado: (2022)

Smoking and multiple sclerosis susceptibility
por: Hedström, Anna Karin, et al.
Publicado: (2013)

Multiple comparisons controversies are about context and costs, not frequentism versus Bayesianism
por: Greenland, Sander, et al.
Publicado: (2019)

Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence
por: Good, Chester B., et al.
Publicado: (2018)

An insightful recollection since the distorted key theory was born about 23 years ago
por: Chou, Kuo-Chen
Publicado: (2019)

Iron deposition and inflammation in multiple sclerosis. Which one comes first?
por: Zivadinov, Robert, et al.
Publicado: (2011)

COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile
por: Ciampi, Ethel, et al.
Publicado: (2020)

Personalizing Medicine and Technologies to Address the Experiences and Needs of People with Multiple Sclerosis
por: Henschke, Adam, et al.
Publicado: (2021)

Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis
por: Shin, Robert K., et al.
Publicado: (2021)

Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
por: Heming, Michael, et al.
Publicado: (2023)

Price Increases and New Drugs Drive Increased Expenditures for Multiple Sclerosis
por: Schafer, Jeremy A., et al.
Publicado: (2010)

Novel Insights on Systemic and Brain Aging, Stroke, Amyotrophic Lateral Sclerosis, and Alzheimer’s Disease
por: Shetty, Ashok K., et al.
Publicado: (2019)

What was right about Kerala’s response to the COVID-19 pandemic?
por: Menon, Jaideep C, et al.
Publicado: (2020)

Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines
por: Rivera, Victor M.
Publicado: (2018)

Paradigms in multiple sclerosis: time for a change, time for a unifying concept
por: Krone, Bernd, et al.
Publicado: (2011)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

The Role for Exosomal microRNAs in Disruption of Regulatory T Cell Homeostasis in Multiple Sclerosis
por: Kimura, Kimitoshi, et al.
Publicado: (2018)

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion
por: Alroughani, Raed, et al.
Publicado: (2019)

Neurofilament light in blood – What more is needed for clinical implementation in multiple sclerosis?
por: Zetterberg, Henrik
Publicado: (2020)

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
por: Rivera, Victor M.
Publicado: (2019)

Attitudes toward vaccination in patients with multiple sclerosis: A report from Iran
por: Ghadiri, Fereshteh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_leuvr8nh9pt2dt6rq6vg17knbc